Chronic Obstructive Pulmonary Disease, COPD Clinical Trial
Official title:
A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR
Verified date | February 2022 |
Source | Viatris Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
Status | Completed |
Enrollment | 207 |
Est. completion date | November 25, 2017 |
Est. primary completion date | November 25, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Subject is a male or female subject 40 years of age or older with a diagnosis of COPD. - Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years. - Subject is willing and able to provide signed and dated written informed consent to participate prior to initiation of any study related procedures. Exclusion Criteria: - Subject has a concurrent disease or condition that, in the opinion of the investigator, would interfere with continued study participation or confound the evaluation of safety and tolerability of the study drug. - Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics. - Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention. |
Country | Name | City | State |
---|---|---|---|
United States | Clinical Research of Rock Hill | Rock Hill | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Mylan Inc. | Theravance Biopharma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Trough FEV1 on Day 29 | FEV1 = forced expiratory volume at one second | Baseline and Day 29 | |
Secondary | Change From Baseline Trough FVC (Forced Vital Capacity) on Day 29 | Baseline and Day 29 | ||
Secondary | Change From Baseline Trough Inspiratory Capacity (IC) on Day 29 | Baseline and Day 29 | ||
Secondary | Change From Baseline Peak FEV1 on Day 29 | Baseline and Day 29 (0-4 hours) | ||
Secondary | Change From Baseline Peak FVC on Day 29 | Baseline and Day 29 (0-4 hours) | ||
Secondary | Summary of Rescue Medication Use: Puffs Per Day | 1 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00108823 -
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
|
Phase 3 | |
Completed |
NCT03064113 -
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT00496470 -
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
|
Phase 4 | |
Completed |
NCT02442206 -
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
|
Phase 4 | |
Completed |
NCT02615795 -
Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02449018 -
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
|
Phase 2 |